0001567619-22-000622.txt : 20220105 0001567619-22-000622.hdr.sgml : 20220105 20220105171639 ACCESSION NUMBER: 0001567619-22-000622 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220103 FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McAnear Justin J. CENTRAL INDEX KEY: 0001786386 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39035 FILM NUMBER: 22512293 MAIL ADDRESS: STREET 1: 10X GENOMICS, INC. STREET 2: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 10x Genomics, Inc. CENTRAL INDEX KEY: 0001770787 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 455614458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: (925) 401-7300 MAIL ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: 10X Genomics, Inc. DATE OF NAME CHANGE: 20190315 4 1 doc1.xml FORM 4 X0306 4 2022-01-03 0 0001770787 10x Genomics, Inc. TXG 0001786386 McAnear Justin J. C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 0 1 0 0 Chief Financial Officer Class A Common Stock 2022-01-03 4 M 0 10000 5.04 A 48819 D Class A Common Stock 2022-01-03 4 S 0 3583 145.1619 D 45236 D Class A Common Stock 2022-01-03 4 S 0 4083 145.9556 D 41153 D Class A Common Stock 2022-01-03 4 S 0 1334 146.9178 D 39819 D Class A Common Stock 2022-01-03 4 S 0 500 148.0440 D 39319 D Class A Common Stock 2022-01-03 4 S 0 500 149.1780 D 38819 D Stock Option (right to buy) 5.04 2022-01-03 4 M 0 10000 0.00 D 2028-11-02 Class A Common Stock 10000 350159 D The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $144.54 to $145.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $145.54 to $146.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $146.54 to $147.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $147.58 to $148.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $148.66 to $149.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This option, originally for 600,000 shares, of which 249,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. /s/ Eric S. Whitaker, as Attorney-in-Fact 2022-01-05